Inhaler efficacy for cough treatment
Pro Research Analysisby 
Searched over 200M research papers
Inhaler Efficacy for Cough Treatment: Key Findings
Inhaled Corticosteroids for Chronic Cough and Cough Variant Asthma
Inhaled corticosteroids (ICS), such as fluticasone and budesonide, are widely used for treating chronic cough, especially when related to airway inflammation or cough variant asthma. Studies show that ICS can modestly reduce cough severity in patients with upper airway cough syndrome (UACS) and unexplained chronic cough (UCC), with better results seen in those whose cough is triggered by cold air or has a shorter duration. Longer treatment courses may be more effective for patients with cough lasting over a year, and side effects are generally mild, such as hoarseness . In children with cough variant asthma, fluticasone inhalation effectively controls symptoms, and longer treatment (six months) reduces relapse rates after stopping the medication, with no significant safety concerns . Similarly, in adults with cough variant asthma, budesonide inhalation improves lung function, reduces inflammation, and enhances immune function, though older age and higher inflammation markers may reduce efficacy 910. Most patients experience significant improvement in cough symptoms with budesonide-formoterol inhalers .
Inhaled Steroids in Otherwise Healthy Adults
For otherwise healthy adults with persistent cough, inhaled fluticasone propionate has been shown to reduce cough scores more than placebo, particularly in nonsmokers. The benefit is less clear in smokers, and baseline allergy or lung function does not seem to affect the response .
Bronchodilators and Alternative Inhaled Therapies
Bronchodilator inhalers, such as terbutaline, are as effective as nebulized lidocaine for short-term cough suppression in patients with chronic obstructive pulmonary disease (COPD). Both treatments significantly reduce cough severity within an hour, and side effects are mild and do not lead to discontinuation .
Novel Inhaled Treatments for Refractory Chronic Cough
Emerging evidence suggests that inhaled alkaline hypertonic divalent salts (HDS) at pH 9 can reduce cough frequency in patients with refractory chronic cough, achieving up to a 35% reduction in cough rate within three days, with no reported adverse events . However, more research is needed to confirm these findings.
Inhaled Therapies in Idiopathic Pulmonary Fibrosis
Inhaled RVT-1601, tested in patients with idiopathic pulmonary fibrosis (IPF) and chronic cough, did not show a significant benefit over placebo in reducing cough frequency or severity. The placebo group also experienced a notable reduction in cough, highlighting the challenge of finding effective inhaled treatments for cough in IPF .
Combination Inhalers and Step-Up Therapy in Asthma
For asthma patients with persistent cough despite medium-dose ICS/long-acting β2-agonist (LABA) therapy, a study is underway to evaluate whether switching to a triple combination inhaler (indacaterol/glycopyrronium/mometasone) or increasing the ICS/LABA dose provides better cough relief. This research aims to guide optimal inhaler strategies for cough-dominant asthma .
Conclusion
Inhaled therapies, especially corticosteroids and bronchodilators, are effective for many types of cough, particularly those related to airway inflammation or asthma. The choice of inhaler, treatment duration, and patient characteristics (such as age and inflammation levels) can influence outcomes. Novel inhaled treatments and combination therapies are being explored for refractory cases, but more evidence is needed to establish their roles. Overall, inhalers remain a cornerstone in the management of cough associated with respiratory diseases, with generally favorable safety profiles 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic